X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SON-080 is a low dose recombinant human interleukin-6 (rhIL-6), which is currently being evaluated for the treatment of chemotherapy-induced peripheral neuropathy.
Lead Product(s): Recombinant Human Interleukin-6
Therapeutic Area: Neurology Product Name: SON-080
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 11, 2024
Details:
Sonnet anticipates using the net proceeds from the offering for research and development, including SON-1010 (IL12-FHAB), a proprietary version of native human IL-12, configured using Sonnet's fully human albumin binding (FHAB®) platform.
Lead Product(s): IL12-FHAB,Atezolizumab
Therapeutic Area: Oncology Product Name: SON-1010
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Chardan
Deal Size: $4.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 25, 2023
Details:
SON-1010 (IL12-FHAB), a proprietary version of IL-12, under development of solid tumors. In POC studies indicated that mIL12-FHAB had significantly higher tumor accumulation, 2.5-4.7 times higher on average at the longer time points, and increased retention when compared to mIL-12.
Lead Product(s): IL12-FHAB
Therapeutic Area: Oncology Product Name: SON-1010
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2023
Details:
SON-1010 is a proprietary version of recombinant human Interleukin 12, configured using the FHAB technology that targets tumor and lymphatictissue, which is being investigated with a fixed dose of atezolizumab for the treatment of platinum-resistant ovarian cancer.
Lead Product(s): SON-1010,Atezolizumab
Therapeutic Area: Oncology Product Name: SON-1010
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2023
Details:
The Company intends to use the net proceeds for research and development, including its lead product SON-1010, a proprietary version of native human IL-12, under development for the treatment of solid tumors.
Lead Product(s): SON-1010
Therapeutic Area: Oncology Product Name: SON-1010
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Chardan Capital Markets
Deal Size: $2.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 28, 2023
Details:
SON-1010 is a proprietary version of recombinant human Interleukin 12 (IL-12), configured using the FHAB technology that targets tumor and lymphatictissue, which is investigated for the treatment of patients with advanced solid tumors.
Lead Product(s): IL12-FHAB,Atezolizumab
Therapeutic Area: Oncology Product Name: SON-1010
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
SON-1010 is a proprietary version of recombinant human Interleukin 12 (IL-12), configured using the FHAB technology that targets tumor and lymphatictissue.
Lead Product(s): IL12-FHAB
Therapeutic Area: Oncology Product Name: SON-1010
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
Net proceeds will be used by Lirum primarily to advance its clinical and preclinical studies and development of lead candidate SON-080, for working capital, and to potentially expand its product candidate pipeline.
Lead Product(s): SON-080
Therapeutic Area: Neurology Product Name: SON-080
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Chardan
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 08, 2023
Details:
SON-1010 is a immunotherapeutic recombinant drug that links unmodified singlechain human IL-12 with the albumin-binding domain. It delivers IL-12 to local tumor tissue and stimulates IFNg, which activates immune cells and increases the production of PD-L1 on tumor cells.
Lead Product(s): IL12-FHAB
Therapeutic Area: Oncology Product Name: SON-1010
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 19, 2023
Details:
SON-1010 (IL12-FHAB) is a candidate immunotherapeutic recombinant drug that links unmodified single-chain human IL-12 with the albumin-binding domain of the single-chain antibody fragment A10m3.
Lead Product(s): IL12-FHAB
Therapeutic Area: Oncology Product Name: SON-1010
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
